India’s BioCon Limited to Buy U.S. Firm for $400M

MUMBAI, April 14 (Reuters) - India’s top biotechnology firm, Biocon Ltd, is in talks to acquire a U.S. firm in a deal valued at $400 million to boost its overseas pharmaceutical distribution network, the Mint newspaper reported on Monday.